Stock DNA
Pharmaceuticals & Biotechnology
INR 13,683 Cr (Small Cap)
71.00
40
0.12%
0.08
19.67%
14.18
Total Returns (Price + Dividend) 
Sudeep Pharma for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Sudeep Pharma Ltd is Rated Hold by MarketsMOJO
Sudeep Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 November 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read More
Sudeep Pharma Ltd is Rated Hold by MarketsMOJO
Sudeep Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 November 2026, providing investors with the latest insights into its performance and outlook.
Read More
Sudeep Pharma Ltd Surges 7.44% to Day's High of Rs 1189.65 — Outperforms Sector by 4.55 Percentage Points
The Sensex advanced 2.53% on 5 Nov 2026, yet Sudeep Pharma Ltd outpaced the broader market with a 7.44% gain, reaching an intraday high of Rs 1189.65. This 4.55-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific momentum shift rather than a mere market tailwind.
Read More Announcements 
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations 2015 Regarding Direction Issued By The Gujarat Pollution Control Board
19-Nov-2026 | Source : BSEDirections Issued by the Gujarat Pollution Control Board
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
03-Nov-2026 | Source : BSESubmission of Transcript for the Earnings call held on 29.10.2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29-Oct-2026 | Source : BSESubmission of Audio Recording of the Earnings call held on 29th October 2026
Corporate Actions 
No Upcoming Board Meetings
Sudeep Pharma Ltd has declared 150% dividend, ex-date: 23 Jul 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 16 Schemes (7.43%)
Held by 26 FIIs (2.93%)
Riva Resources Private Limited (40.35%)
Sbi Healthcare Opportunities Fund (2.85%)
5.43%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 24.28% vs -13.20% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 26.88% vs -17.04% in Jun 2026
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025
YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025